1 ml of the syrup contains 5 mg of fluconazole (Fluconazolum).
Excipients of known effect: liquid maltitol – 723 mg/ml, sodium benzoate (E 211) – 1.808 mg/ml, propylene glycol (E 1520) – 60.797 mg/ml, ethanol – 0.361 mg/ml
Treatment of infections caused by yeast fungi:
vaginal candidiasis,
oral and oesophageal candidiasis,
systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis (pulmonary candidiasis, peritoneal candidiasis, urinary candidiasis),
cryptococcal meningoencephalitis,
cryptococcal meningoencephalitis in AIDS patients,
skin candidiasis.
Prevention: prevention of candidiasis in high risk patients (malignant neoplastic patients, following organ transplants and in patients receiving chemotherapy and/or radiotherapy), in line with applicable guidelines on the treatment of fungal infections.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to other azole derivatives.
Concomitant use of terfenadine, pimozide, astemizole , cisapride (see sec. 4.5 Interactions with other drugs and other forms of interaction)
This is a drug. For safety, use it according to the package insert and only when necessary. If in doubt, consult your doctor or pharmacist.
phone: (+48 22) 742 00 22
informacjaoleku@hasco-lek.pl
1 ml of the syrup contains 5 mg of fluconazole (Fluconazolum).
Excipients of known effect: liquid maltitol – 723 mg/ml, sodium benzoate (E 211) – 1.808 mg/ml, propylene glycol (E 1520) – 60.797 mg/ml, ethanol – 0.361 mg/ml
Treatment of infections caused by yeast fungi:
vaginal candidiasis,
oral and oesophageal candidiasis,
systemic candidiasis, including candidemia, disseminated candidiasis and other forms of invasive candidiasis (pulmonary candidiasis, peritoneal candidiasis, urinary candidiasis),
cryptococcal meningoencephalitis,
cryptococcal meningoencephalitis in AIDS patients,
skin candidiasis.
Prevention: prevention of candidiasis in high risk patients (malignant neoplastic patients, following organ transplants and in patients receiving chemotherapy and/or radiotherapy), in line with applicable guidelines on the treatment of fungal infections.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to other azole derivatives.
Concomitant use of terfenadine, pimozide, astemizole , cisapride (see sec. 4.5 Interactions with other drugs and other forms of interaction)
Przedsiębiorstwo Produkcji
Farmaceutycznej
Hasco-Lek S.A.
st. Żmigrodzka 242e
51-131 Wroclaw
phone: (+48) 71 352 95 22
fax: (+48) 71 352 76 36
hasco@hasco-lek.pl
